1. Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma.

    Journal of Translational Medicine 13(1):2063 (2015) PMID 25779182

    PDF not found
  2. Enhanced FHL2 and TGF-β1 Expression Is Associated With Invasive Growth and Poor Survival in Malignant Melanomas.

    American Journal of Clinical Pathology 143(2):248 (2015) PMID 25596251

    This study examines the expression and the role of four-and-a-half LIM domains protein 2 (FHL2) and transforming growth factor β1 (TGF-β1) in human malignant melanoma. It is determined whether both proteins influence melanoma survival time. We analyzed the immunohistochemical staining intensitie...
  3. TGF-β1-dependent induction and nuclear translocation of FHL2 promotes keratin expression in pilomatricoma.

    Virchows Archiv. A. Pathological Anatomy and Hi... 466(2):199 (2015) PMID 25477051

    Pilomatricoma is a tumour derived from hair matrix cells, which shows progressive keratin expression. Tumorigenesis is frequently associated with activating mutations in β-catenin gene inducing nuclear expression of β-catenin protein. The present study analysed the role of transforming growth fa...
  4. Enhanced FHL2 and TGF-β1 Expression Is Associated With Invasive Growth and Poor Survival in Malignant Melanomas.

    American Journal of Clinical Pathology 143(2):248 (2015) PMID 25596251

    This study examines the expression and the role of four-and-a-half LIM domains protein 2 (FHL2) and transforming growth factor β1 (TGF-β1) in human malignant melanoma. It is determined whether both proteins influence melanoma survival time. We analyzed the immunohistochemical staining intensitie...
  5. Enhanced FHL2 and TGF-β1 Expression Is Associated With Invasive Growth and Poor Survival in Malignant Melanomas.

    American Journal of Clinical Pathology 143(2):248 (2015) PMID 25596251

    This study examines the expression and the role of four-and-a-half LIM domains protein 2 (FHL2) and transforming growth factor β1 (TGF-β1) in human malignant melanoma. It is determined whether both proteins influence melanoma survival time. We analyzed the immunohistochemical staining intensitie...
  6. Nivolumab in Previously Untreated Melanoma without BRAF Mutation

    New England Journal of Medicine 372(4):320 (2015)

    Background Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested...
  7. Nivolumab in previously untreated melanoma without BRAF mutation.

    New England Journal of Medicine 372(4):320 (2015) PMID 25399552

    Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study....
  8. Nivolumab in previously untreated melanoma without BRAF mutation.

    New England Journal of Medicine 372(4):320 (2015) PMID 25399552

    Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study....
  9. Nivolumab in previously untreated melanoma without BRAF mutation.

    New England Journal of Medicine 372(4):320 (2015) PMID 25399552

    Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study....
  10. Nivolumab in previously untreated melanoma without BRAF mutation.

    New England Journal of Medicine 372(4):320 (2015) PMID 25399552

    Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study....
  11. Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma.

    Journal of Translational Medicine 13:2063 (2015) PMID 25779182 PMCID PMC4315270

  12. Host response to human breast Invasive Ductal Carcinoma (IDC) as observed by changes in the stromal proteome.

    Journal of Proteome Research 13(11):4739 (2014) PMID 25244421

    Following initial transformation, tumorigenesis, growth, invasion, and metastasis involves a complex interaction between the transformed tissue and the host, particularly in the microenvironment adjacent to the developing tumor. The tumor microenvironment itself is a unique outcome of the host r...
  13. Host Response to Human Breast Invasive Ductal Carcinoma (IDC) as Observed by Changes in the Stromal Proteome.

    Journal of Proteome Research 13(11):4739 (2014) PMID 25244421

    Following initial transformation, tumorigenesis, growth, invasion, and metastasis involves a complex interaction between the transformed tissue and the host, particularly in the microenvironment adjacent to the developing tumor. The tumor microenvironment itself is a unique outcome of the host r...
  14. Ocular diseases in metastatic cutaneous melanoma: review of 108 consecutive patients in two German tertiary centers.

    Graefe's Archive for Clinical and Experimental ... 252(4):679 (2014) PMID 24449136

    To analyze the incidence and spectrum of ocular disease in patients with metastatic cutaneous melanoma. One hundred and eight consecutive patients with metastatic cutaneous melanoma were screened for ocular diseases using standardized eye examination, including measurement of visual acuity and i...
  15. Metalloproteinases in melanoma.

    European Journal of Cell Biology 93(1-2):23 (2014) PMID 24530009

    Tumour cell adhesion, motility, proteolytic activities and cell receptors have important roles in cancer invasion. These processes are involved from early development of melanoma within the epidermis, to tumour cell invasion of the underlying tissue until intravasation of lymphatic or blood vess...
  16. Metalloproteinases in melanoma.

    European Journal of Cell Biology 93(1-2):23 (2014) PMID 24530009

    Tumour cell adhesion, motility, proteolytic activities and cell receptors have important roles in cancer invasion. These processes are involved from early development of melanoma within the epidermis, to tumour cell invasion of the underlying tissue until intravasation of lymphatic or blood vess...
  17. Health-related quality of life, fatigue, and depression under low-dose IFN-α therapy in melanoma patients.

    Journal of Immunotherapy 37(9):461 (2014) PMID 25304729

    Adjuvant melanoma treatment with interferon-α (IFN-α) has proven to be accompanied by several side effects and to decrease patients' health-related quality of life (HRQOL), fatigue and depression being essential factors at that. Although a large body of evidence exists for HRQOL under IFN-α ther...
  18. Metalloproteinases in melanoma.

    European Journal of Cell Biology 93(1-2):23 (2014) PMID 24530009

    Tumour cell adhesion, motility, proteolytic activities and cell receptors have important roles in cancer invasion. These processes are involved from early development of melanoma within the epidermis, to tumour cell invasion of the underlying tissue until intravasation of lymphatic or blood vess...
  19. Loss of epidermal Evi/Wls results in a phenotype resembling psoriasiform dermatitis.

    Journal of Experimental Medicine 210(9):1761 (2013) PMID 23918954 PMCID PMC3754868

    Cells of the epidermis renew constantly from germinal layer stem cells. Although epithelial cell differentiation has been studied in great detail and the role of Wnt signaling in this process is well described, the contribution of epidermal Wnt secretion in epithelial cell homeostasis remains po...
  20. Enhanced deposition of cartilage oligomeric matrix protein is a common feature in fibrotic skin pathologies.

    Matrix Biology 32(6):325 (2013) PMID 23507196

    Skin fibrosis is characterized by activated fibroblasts and an altered architecture of the extracellular matrix. Excessive deposition of extracellular matrix proteins and altered cytokine levels in the dermal collagen matrix are common to several pathological situations such as localized sclerod...